- Home
- REX vs HROW Comparison
REX vs HROW Comparison
Compare REX & HROW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | REX | HROW |
|---|---|---|
| Founded | 1980 | 1998 |
| Country | United States | United States |
| Employees | N/A | 373 |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.4B |
| IPO Year | 1994 | N/A |
Fundamental Metrics
Financial Performance| Metric | REX | HROW |
|---|---|---|
| Price | $49.38 | $30.86 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $69.86 |
| AVG Volume (30 Days) | 120.6K | ★ 836.2K |
| Earning Date | 05-27-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.50 | N/A |
| Revenue | ★ $650,487,000.00 | N/A |
| Revenue This Year | $19.45 | $31.62 |
| Revenue Next Year | N/A | $50.77 |
| P/E Ratio | $20.02 | ★ N/A |
| Revenue Growth | ★ 1.24 | N/A |
| 52 Week Low | $30.02 | $25.21 |
| 52 Week High | $64.95 | $54.98 |
Technical Indicators
Market Signals| Indicator | REX | HROW |
|---|---|---|
| Relative Strength Index (RSI) | 59.02 | 31.47 |
| Support Level | $31.24 | $29.75 |
| Resistance Level | $53.36 | $41.67 |
| Average True Range (ATR) | 1.71 | 1.91 |
| MACD | -0.18 | -0.98 |
| Stochastic Oscillator | 37.12 | 17.68 |
Price Performance
Historical ComparisonAbout REX REX American Resources Corporation
REX American Resources Corp operates as a holding company, which engages in investment in alternative energy and ethanol production entities. Its operating segments include Ethanol and By-Products. Its products include dried distillers grains, modified distillers grains, and non-food grade corn oil.
About HROW Harrow Inc.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.